A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes
A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes
The purpose of this study is to see if LY900014 compared to insulin lispro (Humalog), both in
 combination with insulin glargine or insulin degludec, is safe and effective in participants
 with type 1 diabetes (T1D).
Inclusion Criteria:

 -  Participants must have T1D for at least 1 year prior to screening and continuously
 using insulin for at least 1 year.

 -  Participants must have HbA1c of ≥7.0 and ≤10.0%.

 -  Participants must have been treated for at least 90 days prior to screening with
 either multiple daily injection(s) (MDI) or premixed analog/human insulin regimens at
 least twice daily.

 -  Participants must have body mass index (BMI) of ≤35.0 kilograms per square meter
 (kg/m2).

 Exclusion Criteria:

 -  Participants must not have used other anti-hyperglycemic medications or therapies
 (inhaled, oral or injectable) except for metformin within 90-days of screening.

 -  Participants must not have had more than 1 severe hypoglycemic episode within 6 months
 of screening.

 -  Participants must not have had more than 1 hospitalization related to hyperglycemia or
 diabetic ketoacidosis within 6 months of screening.